Core Viewpoint - The company has entered into a licensing agreement with Eisai Co., Ltd. for the development, production, and commercialization of its innovative anti-PD-1 monoclonal antibody, Hanshuo® (sulunlimab injection), in Japan, which is expected to enhance the product's international market accessibility and recognition, thereby creating conditions for sustained revenue growth [1][3]. Group 1: Licensing Agreement Details - The company will grant Eisai an exclusive license to commercialize the licensed product in the specified region and field [1] - Eisai will pay the company a total of $75 million as an upfront payment, up to $80.01 million in regulatory milestone payments, up to $233.33 million in commercial sales milestone payments based on annual net sales, and a royalty fee calculated as a double-digit percentage of annual net sales [1] Group 2: Product Information and Market Potential - Hanshuo® has been approved for various indications in China, including first-line treatment for squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsq-NSCLC) [2] - The product has also received approvals in multiple countries and regions, including the EU, UK, and several Southeast Asian countries, and has been granted orphan drug designation in the US and other regions [2] - The global sales of PD-1 targeted monoclonal antibody drugs are projected to reach approximately $45.7 billion in 2024, indicating significant market potential for the licensed product [3]
复宏汉霖(02696.HK)：就汉斯状®与Eisai订立的许可协议 首付款7500万美元